GSK's investment plans get underway in UK and elsewhere
The pharmaceuticals giant has broken ground at Barnard Castle, County Durham, UK and started work at Marburg in Germany
GSK has broken ground this week for its new aseptic sterile manufacturing facility in Barnard Castle, County Durham, UK.
The project is part of GSK’s £92 million investment in the site announced in July 2016.
The site will produce injectable liquids for HIV treatment and respiratory and auto-immune diseases.
Service Design Partnership of Wakefield, UK, which has been working with GSK at the Barnard Castle plant for almost 30 years, is part of the design and construction team.
Barnard Castle is one of GSK’s largest secondary manufacturing sites, employing over 1,000 people and the new facility was given planning approval in February.
Present at the ground breaking were Ian McCubbin, Senior Vice President, GSK, Alastair Leighton, Barnard Castle Site Director, along with the construction project team, GSK apprentices and Strategic Account Manager from Business Durham, Caroline Taukulis.
GSK has also begun work on £140m plant in in Marburg, Germany, designed to increase production meningococcal B vaccine, Bexsero. This will involve moving production for three of the four active components of the meningococcal B vaccine to Marburg.
